Table 2.
PathwayConnector—complementary pathway networks enriched by the HOMA-β network.
| S. No | Pathway | p Value | Common Pathways | Common Genes | Genes Found | Pathway Ratio | Rank |
|---|---|---|---|---|---|---|---|
| 1 | Adherens junction | 4.61653 × 10−26 | 7/4246 | 19/72 | 19/291 | 1.649 × 10−3 | 3 |
| 2 | Type II diabetes mellitus | 1.22599 × 10−13 | 5/4246 | 13/46 | 13/291 | 1.178 × 10−3 | 12 |
| 3 | Chronic myeloid leukemic | 1.35055 × 10−17 | 8/4246 | 18/76 | 18/291 | 1.884 × 10−3 | 4 |
| 4 | Pathways in cancer | 4.61653 × 10−26 | 23/4246 | 52/526 | 52/291 | 5.417 × 10−3 | 1 |
| 5 | ErbB signaling pathway | 7.28619 × 10−15 | 10/4246 | 17/85 | 17/291 | 2.355 × 10−3 | 10 |
| 6 | Bacterial invasion of epithelial cells | 3.71078 × 10−13 | 7/4246 | 15/74 | 15/291 | 1.649 × 10−3 | 15 |
| 7 | Proteoglycans in cancer | 1.21687 × 10−21 | 14/4246 | 30/201 | 30/291 | 3.297 × 10−3 | 2 |
| 8 | Neurotrophin signaling pathway | 4.91599 × 10−17 | 6/4246 | 21/119 | 21/291 | 1.413 × 10−3 | 5 |
| 9 | Pancreatic cancer | 5.48038 × 10−13 | 10/4246 | 14/75 | 14/291 | 2.355 × 10−3 | 16 |
| 10 | Colorectal cancer | 2.16852 × 10−13 | 7/4246 | 19/72 | 19/291 | 1.649 × 10−3 | 3 |
| 11 | Insulin signaling pathway | 1.09957 × 10−15 | 5/4246 | 13/46 | 13/291 | 1.178 × 10−3 | 12 |
| 12 | Focal adhesion | 2.55996 × 10−15 | 8/4246 | 18/76 | 18/291 | 1.884 × 10−3 | 4 |
| 13 | Hepatitis B | 2.3797 × 10−16 | 23/4246 | 52/526 | 52/291 | 5.417 × 10−3 | 1 |
| 14 | Human T-cell leukemic virus 1 infection | 9.37 × 10−15 | 10/4246 | 17/85 | 17/291 | 2.355 × 10−3 | 10 |
| 15 | Rap1 signaling pathway | 6.90707 × 10−15 | 7/4246 | 15/74 | 15/291 | 1.649 × 10−3 | 15 |
| 16 | EGFR tyrosine kinase inhibitor resistance | - | 14/4246 | 30/201 | 30/291 | 3.297 × 10−3 | New |
| 17 | Ras signaling pathway | 3.086743 × 10−13 | 6/4246 | 21/119 | 21/291 | 1.413 × 10−3 | 5 |
| 18 | Non-small cell lung cancer | 1.41 × 10−6 | 10/4246 | 14/75 | 14/291 | 2.355 × 10−3 | 16 |
| 19 | Endometrial cancer | 7.88 × 10−7 | 10/4246 | 15/86 | 15/291 | 2.355 × 10−3 | 13 |
| 20 | MAPK signaling pathway | 1.13 × 10−9 | 7/4246 | 21/137 | 21/291 | 1.649 × 10−3 | 7 |
| 21 | Adipocytokine signaling pathway | 7.72 × 10−7 | 9/4246 | 24/199 | 24/291 | 2.120 × 10−3 | 8 |
| 22 | PI3K-Akt signaling pathway | 6.34 × 10−9 | 11/4246 | 21/163 | 21/291 | 2.591 × 10−3 | 6 |
| 23 | Apoptosis | 1.38 × 10−7 | 12/4246 | 25/219 | 25/291 | 2.826 × 10−3 | 11 |
| 24 | Cell cycle | 2.02 × 10−6 | 9/4246 | 24/206 | 24/291 | 2.120 × 10−3 | 9 |
| 25 | Platinum drug resistance | - | 10/4246 | 12/79 | 12/291 | 2.355 × 10−3 | New |
| 26 | Non-alcoholic fatty liver disease (NAFLD) | 1.36 × 10−5 | 9/4246 | 24/232 | 24/291 | 2.120 × 10−3 | 14 |
| 27 | Bladder cancer | 2.91 × 10−3 | 8/4246 | 10/66 | 10/291 | 1.884 × 10−3 | 69 |
| 28 | mTOR signaling pathway | 2.33 × 10−4 | 9/4246 | 8/58 | 8/291 | 2.120 × 10−3 | 64 |